Vasoactive intestinal peptide producing neuroblastoma.
The Verner-Morrison syndrome has been described in 19 previous patients with ganglioneuroma and ganglioneuroblastoma but never neuroblastoma. Its occurrence following treatment of a neuroblastoma with chemotherapy with maturation of the tumor has only been reported on one previous occasion. Our case suggests that vasoactive intestinal polypeptide may be used not only as a diagnostic indicator for the presence of a neural crest tumor but also as a marker to monitor maturation of the tumor and indicate an improving prognosis.
D007516:Adenoma, Islet Cell / Q000378:metabolism*; D005260:Female; D005729:Ganglioneuroma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D006729:Hormones, Ectopic / Q000378:metabolism*; D006801:Humans; D007223:Infant; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D009384:Paraneoplastic Endocrine Syndromes / Q000175:diagnosis*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism*; D003969:Vipoma / Q000175:diagnosis / Q000378:metabolism*; D014846:Vulvar Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*
D005768:Gastrointestinal Hormones; D006729:Hormones, Ectopic; D014660:Vasoactive Intestinal Peptide